Filgrastim biosimilar - Dong-A ST

Drug Profile

Filgrastim biosimilar - Dong-A ST

Alternative Names: DA 3030; Leucostim; Leukopoeitin - Dong-A ST; Leukostim®; rhG-CSF - Dong-A ST

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Immunostimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Marketed Neutropenia
  • Phase II Diabetic neuropathies

Most Recent Events

  • 05 May 2016 Biocad plans a phase I trial for Leucocytosis (In volunteers) in Russia (SC) (NCT02762799)
  • 01 May 2016 Dong-A ST completes a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
  • 01 Feb 2016 Dong-A ST initiates a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top